( (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled ...

Phase transformations—in which a material changes from one crystal structure to another, thereby acquiring dramatically ...

Tvardi Therapeutics TVRD stock has skyrocketed 148.8% so far this week, reflecting strong investor enthusiasm following a ...

Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the ...

Quantum materials, materials exhibiting physical behavior governed by the laws of quantum mechanics, have proved promising ...

A newly found chain-reaction phase change in 2D MoTe2 lowers energy barriers, enabling faster control of electronic and ...

Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative ...

Globally recognized leader in early-phase oncology clinical development and experimental therapeuticsStrengthens strategic ...

FDA Drug Approvals and Regulatory Updates Drug Pharmacologic class Indication More information Cardiovascular Disease Tryngolza (olezarsen) Apolipoprotein ...

Systemic lupus erythematosus (SLE) is a chronic, complex autoimmune disease that can affect multiple organ systems, with ...

Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital ...